Parenteral versus oral iron therapy for adults and children with chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Albaramki, Jumana ^a   Hodson, Elisabeth M ^a   Craig, Jonathan C ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON;

CHRONIC KIDNEY DISEASE; HEART FUNCTION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; IRON THERAPY; MORTALITY; PERITONEAL DIALYSIS; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 70049096226     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007857     Document Type: Review

References (28)

1. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrology Dialysis Transplantation 2005;20(7):1443-1449 [MEDLINE: 15855210]
2. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology 2000;11(3):530-538 [MEDLINE: 10703677] (Pubitemid 30115083)
3. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clinical Nephrology 1990;34(6):272-278 [MEDLINE: 2073771]
4. McMahon L. Biochemical and haematological targets. http://www.cari.org. au/DIALYSIS-bht-published/Haemoglobin-Aug-2008.pdf 2008. [DOI: 10.1111/j.1440-1797.2008.00997.x]
5. DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clinical Nephrology 2003;60(5):335-340 [MEDLINE: 14640239] (Pubitemid 37407691)
6. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases 1995;26(1):41-46 [MEDLINE: 7611266]
7. Fishbane S. Iron management in nondialysis-dependent CKD. American Journal of Kidney Diseases 2007;49(6):736-743 [MEDLINE: 17533016]
8. Gillespie RS, Wolf FM. Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatric Nephrology 2004; 19(6):662-666 [MEDLINE: 15052462]
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560 [MEDLINE: 12958120]
10. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008. Available from www.cochranehandbook.org.
11. Jacobs C, Horl WH, Macdougall IC, Valderrabano F, Parrondo I, Abraham IL, et al. European best practice guidelines 9-13: anaemia management. Nephrology Dialysis Transplantation 2000;15 Suppl 4:33-42. [MEDLINE: 11052147]
12. Johnson DW. Intravenous versus oral iron supplementation in peritoneal dialysis patients. Peritoneal Dialysis International 2007;27 Suppl 2:S255-60. [MEDLINE: 17556315]
13. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. http://www.kidney.org/PROFESSIONALS/kdoqi/ guidelines-anemiaUP/index.htm 2007.
14. Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Seminars in Dialysis 2006;19(2):146-151 [MEDLINE: 16551293]
15. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org.
16. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).Nephrology Dialysis Transplantation 2004;19(1):121-132 [MEDLINE: 14671047] (Pubitemid 38072621)
17. Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, et al. Clinical Practice Guidelines for assessment and management of iron deficiency. Kidney International - Supplement 2008, (S110):S7-S11. [MEDLINE: 18668119]
18. United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed March 2009).
19. McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases 2008;51(4 Suppl 2):S46-55.
20. Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. American Journal of Kidney Diseases 1997;30(6):912-922 [MEDLINE: 9398141] (Pubitemid 27524360)
21. Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Klarenbach SW, et al. Clinical practice guidelines for evidence-based use of erythropoietic- stimulating agents. Kidney International - Supplement 2008, (110):S12-8. [MEDLINE: 18668116]
22. Muller-Wiefel DE, Sinn H, Gilli G, Scharer K. Hemolysis and blood loss in children with chronic renal failure. Clinical Nephrology 1977;8(5):481-486 [MEDLINE: 589879] (Pubitemid 8233939)
23. Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovascular Drugs & Therapy 2008;22(1):37-44. [MEDLINE: 18095148]
24. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369(9559):381-388 [MEDLINE: 17276778] (Pubitemid 46188479)
25. Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC. Cochrane Renal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 1. Art. No.: RENAL (accessed March 2009).
26. Rozen-Zvi B, Gafter-Gvilli A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review andmeta-analysis. American Journal of Kidney Diseases 2008;52(5):897-906. [MEDLINE: 18845368]
27. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [DOI: 10.1186/1745-6215-8-16; : http://www.trialsjournal.com/content/ 8/1/16] (Pubitemid 47161711)
28. Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatmentmay improve quality of life and cognitive function in chronic hemodialysis patients. American Journal of Kidney Diseases 1989;14(6):478-485 [MEDLINE: 2596475] (Pubitemid 20057895)